WHO leaves key lung cancer drugs off new essential medicines list
They have been used for the treatment of nonsmall cell lung cancer before, but the WHO says more work needs to be done on Keytruda, Opdivo and Tecentriq
09 July 2019 - 18:10
Geneva/Zurich — Immunotherapies that have emerged as a breakthrough in treating lung cancer have been rejected for inclusion on the World Health Organisation’s (WHO’s) list of “essential medicines”, which received a biennial update on Tuesday.
The list, which includes treatments that the WHO regards as global standards that should be available everywhere, aims to help governments make the best choices for their health systems...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.